Biomea Fusion, Inc. (NASDAQ:BMEA – Free Report) – Research analysts at HC Wainwright raised their Q2 2025 earnings estimates for shares of Biomea Fusion in a research note issued to investors on Monday, June 23rd. HC Wainwright analyst J. Pantginis now forecasts that the company will earn ($0.46) per share for the quarter, up from their previous estimate of ($0.66). HC Wainwright has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Biomea Fusion’s current full-year earnings is ($3.93) per share. HC Wainwright also issued estimates for Biomea Fusion’s Q3 2025 earnings at ($0.41) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.92) EPS, FY2026 earnings at ($1.86) EPS, FY2027 earnings at ($2.14) EPS and FY2028 earnings at ($2.27) EPS.
Biomea Fusion (NASDAQ:BMEA – Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The company reported ($0.80) EPS for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.04.
Get Our Latest Stock Analysis on BMEA
Biomea Fusion Stock Down 9.0%
Shares of BMEA opened at $1.81 on Thursday. Biomea Fusion has a 52-week low of $1.29 and a 52-week high of $13.07. The company has a market capitalization of $68.00 million, a PE ratio of -0.51 and a beta of -0.23. The stock has a fifty day simple moving average of $1.94 and a two-hundred day simple moving average of $2.86.
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in BMEA. CWM LLC raised its stake in Biomea Fusion by 8,058.5% during the 1st quarter. CWM LLC now owns 16,888 shares of the company’s stock valued at $36,000 after acquiring an additional 16,681 shares in the last quarter. Cerity Partners LLC bought a new stake in Biomea Fusion during the 1st quarter valued at $37,000. Bayesian Capital Management LP bought a new stake in Biomea Fusion during the 4th quarter valued at $42,000. Wells Fargo & Company MN raised its stake in Biomea Fusion by 51.7% during the 4th quarter. Wells Fargo & Company MN now owns 12,914 shares of the company’s stock valued at $50,000 after acquiring an additional 4,399 shares in the last quarter. Finally, Intech Investment Management LLC bought a new stake in Biomea Fusion during the 4th quarter valued at $54,000. Institutional investors and hedge funds own 96.72% of the company’s stock.
About Biomea Fusion
Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.
Read More
- Five stocks we like better than Biomea Fusion
- Insider Trading – What You Need to Know
- EA Just Caught a Monster Upgrade: Bullish Breakout Ahead?
- Manufacturing Stocks Investing
- 3 Stocks Hitting All-Time Highs With More Room to Run
- Most active stocks: Dollar volume vs share volume
- QuantumScape Soars 30%: What Drove the Next-Gen EV Stock’s Rally
Receive News & Ratings for Biomea Fusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomea Fusion and related companies with MarketBeat.com's FREE daily email newsletter.